AMARIN CORP PLC\UK Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
AMARIN CORP PLC\UK (AMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $5.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-02
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $5.70M, a 21.92% decline from fiscal 2024.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $7.30M, a 10.98% decline from fiscal 2023.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $8.20M, a 50.60% decline from fiscal 2022.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $16.60M, a 21.33% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2025-12-31 | $5.70M 10-K · filed 2026-03-02 |
| 2024-12-31 | $7.30M 10-K · filed 2026-03-02 |
| 2023-12-31 | $8.20M 10-K · filed 2026-03-02 |
| 2022-12-31 | $16.60M 10-K · filed 2025-03-12 |
| 2021-12-31 | $21.10M 10-K · filed 2024-02-29 |
| 2020-12-31 | $22.50M 10-K · filed 2023-03-01 |
| 2019-12-31 | $14.50M 10-K · filed 2022-03-01 |
| 2018-12-31 | $7.70M 10-K · filed 2021-02-25 |
| 2017-12-31 | $7.10M 10-K · filed 2020-02-25 |
| 2016-12-31 | $6.50M 10-K · filed 2019-02-27 |
| 2015-12-31 | $9.10M 10-K · filed 2018-02-27 |
| 2014-12-31 | $8.10M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |